RECIST 1.1 AND irRC FOR RESPONSE ASSESMENT IN PATIENTS WITH DISSEMINATED CUTANEOUS MELANOMA TREATED WITH IPILIMUMAB OR DENDRITIC CELL VACCINE

Special systems were developed for response assessment of immunooncology drugs. The role and benefits of particular system in assessing the efficacy of different immunotherapy methods are not clear yet. The objective of this study is to compare the responses on ipilimab (IPI) or dendritic cell vacci...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: A. V. Novik, E. V. Yaremenko, E. M. Anokhina, T. L. Nehaeva, A. I. Semenova, D. Kh. Latipova, S. A. Protsenko, I. A. Baldueva
Formato: Artigo
Idioma:Russo
Publicado: Tomsk National Research Medical Center of the Russian Academy of Sciences 2019-09-01
Series:Sibirskij Onkologičeskij Žurnal
Assuntos:
melanoma
ipilimumab
dendritic cell vaccines
recist 1.1
irrc
response assessment
immunotherapy
Acceso en liña:https://www.siboncoj.ru/jour/article/view/1136
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares